Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in Rhesus Macaques

Clinical and Vaccine Immunology

Volumn 21, Issue 11, 2014, Pages 1512-1520

  Chen, Ligong ^a,c   Schiffer, Jarad M ^a   Dalton, Shannon ^a,b   Sabourin, Carol L ^b   Niemuth, Nancy A ^b   Plikaytis, Brian D ^a   Quinn, Conrad P ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c Atlanta Research and Education Foundation Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN PROTECTIVE ANTIGEN; ANTHRAX VACCINE; ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 4; UNCLASSIFIED DRUG; ANTHRAX TOXIN; BACTERIAL ANTIGEN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; BIOLOGICAL MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; NONHUMAN; RECEIVER OPERATING CHARACTERISTIC; RHESUS MONKEY; SURVIVAL; TOXIN NEUTRALIZATION ACTIVITY; TREATMENT DURATION; ANIMAL; BLOOD; DISEASE MODEL; GENE EXPRESSION PROFILING; IMMUNOLOGY; LYMPHOCYTE; MORTALITY; PROCEDURES; RESPIRATORY TRACT INFECTIONS; SURVIVAL ANALYSIS; VACCINATION;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BIOMARKERS; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; LYMPHOCYTES; MACACA MULATTA; RESPIRATORY TRACT INFECTIONS; SURVIVAL ANALYSIS; VACCINATION;

EID: 84914692870     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00469-14     Document Type: Article

References (37)

1. Saile E, Quinn CP. 2010. Anthrax vaccines, p 269-293. In Bergman NH (ed), Bacillus anthracis and anthrax. Wiley-Blackwell, Hoboken, NJ.
2. Bienek DR, Loomis LJ, Biagini RE. 2009. The anthrax vaccine: no new tricks for an old dog. Hum. Vaccin. 5:184-189. http://dx.doi.org/10.4161/hv.5.3.7308.
3. Gronvall GK, Trent D, Borio L, Brey R, Nagao L, Alliance for Biosecurity. 2007. The FDA animal efficacy rule and biodefense. Nat. Biotechnol. 25:1084-1087. http://dx.doi.org/10.1038/nbt1007-1084.
4. Fay MP, Follmann DA, Lynn F, Schiffer JM, Stark GV, Kohberger R, Quinn CP, Nuzum EO. 2012. Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge. Sci. Transl. Med. 4:151ra126. http://dx.doi.org/10.1126/scitranslmed.3004073.
5. McBride BW, Mogg A, Telfer JL, Lever MS, Miller J, Turnbull PC, Baillie L. 1998. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 16:810-817. http://dx.doi.org/10.1016/S0264-410X(97)00268-5.
6. Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D. 2010. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine 28:1056-1061. http://dx.doi.org/10.1016/j.vaccine.2009.10.111.
7. Turnbull PC, Broster MG, Carman JA, Manchee RJ, Melling J. 1986. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect. Immun. 52:356-363.
8. Turnbull PC, Leppla SH, Broster MG, Quinn CP, Melling J. 1988. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med. Microbiol. Immunol. 177:293-303.
9. Keitel WA, Treanor JJ, El Sahly HM, Evans TG, Kopper S, Whitlow V, Selinsky C, Kaslow DC, Rolland A, Smith LR, Lalor PA. 2009. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum. Vaccin. 5:536-544.http://dx.doi.org/10 .4161/hv.5.8.8725.
10. Luxembourg A, Hannaman D, Nolan E, Ellefsen B, Nakamura G, Chau L, Tellez O, Little S, Bernard R. 2008. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine 26:5216-5222. http://dx.doi.org/10.1016/j.vaccine.2008.03.064.
11. Brachman PS, Gold H, Plotkin SA, Fekety FK, Werrin M, Ingraham NR. 1962. Field evaluation of human anthrax vaccine. Am. J. Public Health Nations Health 52:632-645. http://dx.doi.org/10.2105/AJPH.52.4.632.
12. Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, Freeman AE, Li H, Mulligan MJ, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Soroka SD, Fox SP, Stamper JL, McNeil MM, Perkins BA, Messonnier N, Quinn CP, Anthrax Vaccine Research Program Working Group. 2008. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 300:1532-1543. http://dx.doi.org/10.1001/jama.300.13.1532.
13. Wright JG, Plikaytis BD, Rose CE, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Semenova VA, Li H, Schiffer J, Dababneh H, Martin SK, Martin SW, Marano N, Messonier NE, Quinn CP. 2014. Non-inferiority and safety of reduced schedules and intramuscular injection of anthrax vaccine adsorbed (AVA). Vaccine 32: 1019-1028. http://dx.doi.org/10.1016/j.vaccine.2013.10.039.
14. Institute of Medicine (US) Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program. 2002. An assessment of the CDC anthrax vaccine safety and efficacy research program. National Academies Press, Washington, DC.
15. Quinn CP, Sabourin CL, Niemuth NA, Li H, Semenova VA, Rudge TL, Mayfield HJ, Schiffer J, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Brys AM, Hunt RE, Levesque D, Estep JE, Barnewall RE, Robinson DM, Plikaytis BD, Marano N, AVRP Laboratory Working Group. 2012. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques. Clin. Vaccine Immunol. 19:1730-1745. http://dx.doi .org/10.1128/CVI.00324-12.
16. Scola MP, Thompson SD, Brunner HI, Tsoras MK, Witte D, Van Dijk MA, Grom AA, Passo MH, Glass DN. 2002. Interferon-gamma: interleukin-4 ratios and associated type 1 cytokine expression in juvenile rheumatoid arthritis synovial tissue. J. Rheumatol. 29:369-378.
17. Shirai A, Conover J, Klinman DM. 1995. Increased activation and altered ratio of interferon-gamma:interleukin-4 secreting cells in MRL-lpr/lpr mice. Autoimmunity 21: 107-116. http://dx.doi.org/10.3109/08916939508993357.
18. Friedman J, Hastie T, Tibshirani R. 2010. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33:1-22. http://dx.doi.org/10.1111/j.1467-9868.2005.00503.x.
19. Zou H, Hastie T. 2005. Regularization and variable selection via the elastic net. J. R. Stat. Soc. 67:301-320. http://dx.doi.org/10.1111/j.1467-9868.2005.00503.x.
20. Waldron L, Pintilie M, Tsao MS, Shepherd FA, Huttenhower C, Jurisica I. 2011. Optimized application of penalized regression methods to diverse genomic data. Bioinformatics 27:3399-3406. http://dx.doi.org/10.1093/bioinformatics/btr591.
21. Genkin A, Lewis DD, Madigan D. 2007. Large-scale Bayesian logistic regression for text categorization. Technometrics 49:291-304. http://dx.doi.org/10.1198/004017007000000245.
22. Hastie T, Tibshirani R, Friedman J. 2009. The elements of statistical learning: data mining, inference, and prediction, 2nd ed. Springer-Verlag, New York, NY.
23. Heymans MW, van Buuren S, Knol DL, van Mechelen W, de Vet HCW. 2007. Variable selection under multiple imputation using the bootstrap in a prognostic study. BMC Med. Res. Methodol. 7:33. http://dx.doi.org/10.1186/1471-2288-7-33.
24. Austin PC, Tu JV. 2004. Bootstrap methods for developing predictive models. Am. Stat. 58:131-137. http://dx.doi.org/10.1198/0003130043277.
25. Venkatraman ES. 2000. A permutation test to compare receiver operating characteristic curves. Biometrics 56:1134-1138. http://dx.doi.org/10.1111/j.0006-341X.2000.01134.x.
26. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M. 2011. pROC: an open-source package for R and S - to analyze and compare ROC curves. BMC Bioinformatics 12:77. http://dx.doi.org/10 .1186/1471-2105-12-77.
27. Ionin B, Hopkins RJ, Pleune B, Sivko GS, Reid FM, Clement KH, Rudge TL, Jr, Stark GV, Innes A, Sari S, Guina T, Howard C, Smith J, Swoboda ML, Vert-Wong E, Johnson V, Nabors GS, Skiadopoulos MH. 2013. Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis. Clin. Vaccine Immunol. 20:1016-1026. http://dx.doi.org/10.1128/CVI.00099-13.
28. Allison PD. 1999. Multiple regression: a primer. Pine Forge Press, Thousand Oaks, CA.
29. Belsley DA, Kuh K, Welsch RE. 1980. Regression diagnostics: identifying influential data and sources of collinearity. John Wiley & Sons, New York, NY.
30. Thorne CB, Belton FC. 1957. An agar-diffusion method for titrating Bacillus anthracis immunizing antigen and its application to a study of antigen production. J. Gen. Microbiol. 17:505-516. http://dx.doi.org/10.1099/00221287-17-2-505.
31. Little SF, Webster WM, Ivins BE, Fellows PF, Norris SL, Andrews GP. 2004. Development of an in vitro-based potency assay for anthrax vaccine. Vaccine 22:2843-2852. http://dx.doi.org/10.1016/j.vaccine.2003.12.027.
32. Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, Gibbs P, Dertzbaugh M, Friedlander AM. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19:4768-4773. http://dx.doi.org/10.1016/S0264-410X(01)00234-1.
33. Reuveny A, White MD, Adar YY, Kafri Y, Altboum YZ, Gozes Y, Kobiler D, Shafferman A, Velan B. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69:2888-2893. http://dx.doi.org/10.1128/IAI.69.5.2888-2893.2001.
34. Pittman PR, Gibbs PH, Cannon TL, Friedlander AM. 2002. Anthrax vaccine: short-term safety experience in humans. Vaccine 20:972-978. http://dx.doi.org/10.1016/S0264-410X(01)00387-5.
35. Pittman PR, Fisher D, Quinn X, Schmader T, Barrera-Oro JG. 2013. Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity. Vaccine 31: 5009-5014. http://dx.doi.org/10.1016/j.vaccine.2013.08.086.
36. Swets JA. 1988. Measuring the accuracy of diagnostic systems. Science 240:1285-1293. http://dx.doi.org/10.1126/science.3287615.
37. Semenova VA, Schiffer J, Steward-Clark E, Soroka S, Schmidt DS, Brawner MM, Lyde F, Thompson R, Brown N, Foster L, Fox S, Patel N, Freeman AE, Quinn CP. 2012. Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG. J. Immunol. Methods 376:97-107. http://dx.doi.org/10.1016/j.jim.2011.12.002.